The hexosamine biosynthesis pathway is a targetable liability in lung cancers with concurrent KRAS and LKB1 mutations
暂无分享,去创建一个
B. Faubert | R. Deberardinis | J. Minna | L. Girard | L. Cai | K. Unsal-Kaçmaz | S. Kasiri | Xiankai Sun | Bookyung Ko | Chendong Yang | Akash K. Kaushik | Hui Wang | Kailong Li | James Kim | Wen Gu | Nefertiti Muhammad | Hyun Min Lee | Kien Nham | Feng Cai | M. Haloul | Jiyeon Kim | U. Marriam
[1] C. Des Rosiers,et al. First characterization of glucose flux through the hexosamine biosynthesis pathway (HBP) in ex vivo mouse heart , 2020, The Journal of Biological Chemistry.
[2] J. Heymach,et al. Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy , 2019, Nature Reviews Cancer.
[3] J. Ferreira,et al. Protein Glycosylation and Tumor Microenvironment Alterations Driving Cancer Hallmarks , 2019, Front. Oncol..
[4] R. Deberardinis,et al. Inosine Monophosphate Dehydrogenase Dependence in a Subset of Small Cell Lung Cancers. , 2018, Cell metabolism.
[5] J. Szustakowski,et al. STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma. , 2018, Cancer discovery.
[6] Rosa Maria Moresco,et al. Inhibition of the Hexosamine Biosynthetic Pathway by targeting PGM3 causes breast cancer growth arrest and apoptosis , 2018, Cell Death & Disease.
[7] James E. Verdone,et al. O-GlcNAcylation is required for mutant KRAS-induced lung tumorigenesis , 2018, The Journal of clinical investigation.
[8] Jennifer J. Kohler,et al. Effects of altered sialic acid biosynthesis on N-linked glycan branching and cell surface interactions , 2017, The Journal of Biological Chemistry.
[9] Benjamin P. C. Chen,et al. CPS1 maintains pyrimidine pools and DNA synthesis in KRAS/LKB1-mutant lung cancer cells , 2017, Nature.
[10] B. Viollet,et al. GFAT1 phosphorylation by AMPK promotes VEGF-induced angiogenesis. , 2017, The Biochemical journal.
[11] Kristofer C. Berrett,et al. MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition. , 2017, Cancer cell.
[12] S. Armstrong,et al. ENL links histone acetylation to oncogenic gene expression in AML , 2017, Nature.
[13] Yuanyuan Ruan,et al. High expression of GFAT1 predicts poor prognosis in patients with pancreatic cancer , 2016, Scientific Reports.
[14] R. Deberardinis,et al. Fatty Acid Oxidation Mediated by Acyl-CoA Synthetase Long Chain 3 Is Required for Mutant KRAS Lung Tumorigenesis. , 2016, Cell reports.
[15] P. Jänne,et al. Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS-Mutant Lung Adenocarcinoma , 2015, Clinical Cancer Research.
[16] Naoyuki Taniguchi,et al. Glycans and cancer: role of N-glycans in cancer biomarker, progression and metastasis, and therapeutics. , 2015, Advances in cancer research.
[17] G. Hart,et al. Nutrient regulation of signaling, transcription, and cell physiology by O-GlcNAcylation. , 2014, Cell metabolism.
[18] Steven J. M. Jones,et al. Comprehensive molecular profiling of lung adenocarcinoma , 2014, Nature.
[19] R. Deberardinis,et al. Oxidation of alpha-ketoglutarate is required for reductive carboxylation in cancer cells with mitochondrial defects. , 2014, Cell reports.
[20] A. Antebi,et al. Hexosamine Pathway Metabolites Enhance Protein Quality Control and Prolong Life , 2014, Cell.
[21] L. Borsig,et al. Altered Tumor-Cell Glycosylation Promotes Metastasis , 2014, Front. Oncol..
[22] Channing J Der,et al. KRAS: feeding pancreatic cancer proliferation. , 2014, Trends in biochemical sciences.
[23] Jan Budczies,et al. Online Survival Analysis Software to Assess the Prognostic Value of Biomarkers Using Transcriptomic Data in Non-Small-Cell Lung Cancer , 2013, PloS one.
[24] Michael Peyton,et al. Systematic Identification of Molecular Subtype-Selective Vulnerabilities in Non-Small-Cell Lung Cancer , 2013, Cell.
[25] David A. Scott,et al. Genome engineering using the CRISPR-Cas9 system , 2013, Nature Protocols.
[26] Travis J Cohoon,et al. Metabolic and functional genomic studies identify deoxythymidylate kinase as a target in LKB1-mutant lung cancer. , 2013, Cancer discovery.
[27] Liu Wei,et al. LKB1 inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin. , 2013, Cancer cell.
[28] Le Cong,et al. Multiplex Genome Engineering Using CRISPR/Cas Systems , 2013, Science.
[29] Gerald C. Chu,et al. Oncogenic Kras Maintains Pancreatic Tumors through Regulation of Anabolic Glucose Metabolism , 2012, Cell.
[30] D. Hardie,et al. AMPK: a nutrient and energy sensor that maintains energy homeostasis , 2012, Nature Reviews Molecular Cell Biology.
[31] T. Lefebvre,et al. The hexosamine biosynthetic pathway and O-GlcNAcylation drive the expression of β-catenin and cell proliferation. , 2012, American journal of physiology. Endocrinology and metabolism.
[32] G. Hart,et al. O-GlcNAc signaling: a metabolic link between diabetes and cancer? , 2010, Trends in biochemical sciences.
[33] Jason I. Herschkowitz,et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer , 2010, Breast Cancer Research.
[34] J. Hanover,et al. The hexosamine signaling pathway: O-GlcNAc cycling in feast or famine. , 2010, Biochimica et biophysica acta.
[35] J. Dennis,et al. Metabolism, Cell Surface Organization, and Disease , 2009, Cell.
[36] R. Shaw,et al. The LKB1–AMPK pathway: metabolism and growth control in tumour suppression , 2009, Nature Reviews Cancer.
[37] D. Neil Hayes,et al. LKB1 modulates lung cancer differentiation and metastasis , 2007, Nature.
[38] J. Dennis,et al. Complex N-Glycan Number and Degree of Branching Cooperate to Regulate Cell Proliferation and Differentiation , 2007, Cell.
[39] Pablo Tamayo,et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[40] J. Kuromitsu,et al. cDNA cloning and mapping of a novel subtype of glutamine:fructose-6-phosphate amidotransferase (GFAT2) in human and mouse. , 1999, Genomics.
[41] N. Barzilai,et al. The Tissue Concentration of UDP-N-acetylglucosamine Modulates the Stimulatory Effect of Insulin on Skeletal Muscle Glucose Uptake* , 1997, The Journal of Biological Chemistry.
[42] P. Paty,et al. Beta 1-6 branching of N-linked carbohydrate is associated with K-ras mutation in human colon carcinoma cell lines. , 1995, Biochemical and biophysical research communications.
[43] J. Neefjes,et al. Ras (proto)oncogene induces N‐linked carbohydrate modification: temporal relationship with induction of invasive potential. , 1988, The EMBO journal.
[44] E. Racker,et al. Glycolysis and methylaminoisobutyrate uptake in rat-1 cells transfected with ras or myc oncogenes. , 1985, Proceedings of the National Academy of Sciences of the United States of America.
[45] S. Kornfeld,et al. Assembly of asparagine-linked oligosaccharides. , 1985, Annual review of biochemistry.
[46] J E Seegmiller,et al. Regulation of de novo purine biosynthesis in human lymphoblasts. Coordinate control of proximal (rate-determining) steps and the inosinic acid branch point. , 1976, The Journal of biological chemistry.
[47] D. Longnecker,et al. Adenocarcinoma of the pancreas in azaserine-treated rats. , 1975, Cancer research.